Pirlindole
Pirlindole (Lifril, Pyrazidol) is mainly a reversible inhibitor of monoamine oxidase A (RIMA) and secondly a SNRI which was developed and is used in Russia as an antidepressant.[2] It is structurally and pharmacologically related to metralindole.
 | |
| Clinical data | |
|---|---|
| Trade names | Pirazidol |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 20–30% |
| Protein binding | 95% |
| Metabolism | hepatic |
| Onset of action | 2 to 8 hours |
| Elimination half-life | up to 8 days [1] |
| Excretion | urine (50–70%), feces (25–45%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C15H18N2 |
| Molar mass | 226.323 g·mol−1 |
| 3D model (JSmol) | |
| |
See also
References
- Pöldinger W (1985). "Pirlindole: results of an open clinical study in out-patients and of a double-blind study against maprotiline.". Psychiatry the State of the Art. Boston, MA.: Springer. pp. 283–289. doi:10.1007/978-1-4613-2363-1_44. ISBN 978-1-4613-2363-1.
- Bruhwyler, J.; Liégeois, J.F.; Géczy, J. (July 1997). "PIRLINDOLE: A SELECTIVE REVERSIBLE INHIBITOR OF MONOAMINE OXIDASE A. A REVIEW OF ITS PRECLINICAL PROPERTIES". Pharmacological Research. 36 (1): 23–33. doi:10.1006/phrs.1997.0196.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.